Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

Breast Cancer Research

Volumn 12, Issue 3, 2010, Pages

  Van Poznak, Catherine ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CALCIUM; VITAMIN D;

ADJUVANT THERAPY; BONE ATROPHY; BONE DENSITY; BREAST CANCER; EARLY CANCER; EDITORIAL; ENZYME INHIBITION; FEMALE; FOOD AND DRUG ADMINISTRATION; FRACTURE; HUMAN; MULTICENTER STUDY (TOPIC); OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; NOTE; PATHOLOGY; AMENORRHEA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FRAGILITY FRACTURE; HIGH RISK PATIENT; LOW RISK PATIENT; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; RISK REDUCTION; TREATMENT RESPONSE; UNITED STATES; VITAMIN SUPPLEMENTATION;

AROMATASE; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 78149473324     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2584     Document Type: Editorial

References (12)

1. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 2010, 12:R24. 10.1186/bcr2565, 2879572, 20398352.
2. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342. 10.1158/1078-0432.CCR-07-5101, 18829518.
3. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975. 10.1200/JCO.2009.24.5902, 20065185.
4. Chapurlat RD, Delmas PD. Drug Insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006, 2:211-219. 10.1038/ncpendmet0121, 16932286.
5. Penning-van Beest FJA, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008, 24:1337-1344. 10.1185/030079908X297358, 18380910.
6. Cramer JA, Lynch NO, Gaudin A-F, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006, 28:1686-1694. 10.1016/j.clinthera.2006.10.013, 17157124.
7. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85. 10.3816/CBC.2009.n.015, 19433387.
8. Gnant M, Mlineritsch B, Lushin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, . Austrian Breast and Colorectal Cancer Study Group (ABCSG) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849. 10.1016/S1470-2045(08)70204-3, 18718815, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
9. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast 2010, 19:92-96. 10.1016/j.breast.2009.12.001, 20079640.
10. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007, 13:5406-5410. 10.1158/1078-0432.CCR-07-0247, 17875770.
11. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008, 26:5465-5476. 10.1200/JCO.2008.18.4184, 18955443.
12. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebocontrolled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer, 2009. J Clin Oncol 2009, 27:1047-1053. 10.1200/JCO.2008.19.1783, 2667810, 19075260.